A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Coronary artery disease; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Nov 2013 Pooled tolerability analysis assessing the incidence of cardiovascular events presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 30 Aug 2013 Results published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top